TrialEuropean journal of neurology2025

Glial Fibrillary Acidic Protein as a Marker of Disease in Relapsing Multiple Sclerosis: Post Hoc Analysis of Phase 3 Ozanimod Trials.

Sarah Harris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.